Philmans Pharm, Cenedella.de, The German Patient Roundtable

Est. 1977

ALGAE DYNAMICS CORP ENTERS INTO A LETTER OF INTENT WITH BONIFY TO PRODUCE UNIQUE CANNABIS OIL PRODUCTS; ACCELERATES GO-TO-MARKET STRATEGY

RADINZ_LAYOUT

 

 

ALGAE DYNAMICS CORP ENTERS INTO A LETTER OF INTENT
WITH BONIFY TO PRODUCE UNIQUE CANNABIS OIL PRODUCTS;
ACCELERATES GO-TO-MARKET STRATEGY

TORONTO--August 16, 2017--ALGAE DYNAMICS CORP (OTCQB: ADYNF) (the "Company"), a
company focused on the development of unique health products and pharmaceuticals utilizing cannabis
and algae oils, today announced that it has further refined its relationship with 6779264 Manitoba Ltd dba
Bonify (“Bonify”) in a Letter of Intent (“LOI”) dated August 10, 2017. Bonify is a Licensed Producer,
pursuant to the Access to Cannabis for Medical Purposes Regulations in Canada, with the capability to
grow multiple strains of cannabis in its state-of-the-art 320,000 square foot facility.
The Company previously announced a Memorandum of Understanding with Bonify on May 9, 2017, in
which Bonify agreed to supply raw cannabis plant material for processing into cannabis oil for sale and
for use in research. In the recently completed LOI, the Company and Bonify have outlined the following:
1) The purchase and installation of cannabis oil extraction equipment by the Company in Bonify’s
facility;
2) The processing of cannabis material supplied by Bonify and other Licensed Producers in the oil
extraction facility;
3) The supply of cannabis oil and algae omega-3 oils to The University of Waterloo and University of
Western Ontario to support the Sponsored Research Agreements that the Company has in place with
the two universities; and
4) The sharing of direct expenses, and, after adjustment for the market value of cannabis material
supplied by Bonify and third parties, sharing of revenues from the sale of cannabis oil and algaecannabis
oil products.
The term of the agreement is for three years from the commencement of operations and is renewable by
mutual agreement. The Company and Bonify agree to use best efforts to complete formal documentation of
the agreement by September 30, 2017. Upon termination of the agreement, the Company agrees to transfer
title of the equipment to Bonify. The Company has engaged investment bankers to assist with the raising of
necessary capital to purchase and install the extraction equipment.
Given the favorable terms of this agreement, the Company does not anticipate moving forward with its
previously announced joint venture with ARA – Avanti Rx Analytics Inc. in which it was contemplated that
oil extraction would be done utilizing the latter’s facility.
Assuming that all regulatory approvals are in place, initial revenues are expected within six to nine months
following completion of financing,
Paul Ramsay, Chairman and President of Algae Dynamics Corp, stated, “We believe this Letter of Intent
gives us an improved pathway to early revenues as well as a reliable high-quality source of cannabis oil for
the universities to support our important algae-cannabis oil research. We look forward to expeditiously
completing this agreement.”
Jeff Peitsch, President and CEO of Bonify, commented, “Our team is pleased to be working with Algae
Dynamics Corp in support of the Company’s ongoing research and product development work with
universities. We see many benefits to working together with innovative companies such as Algae Dynamics
in this burgeoning cannabis market.”
About Bonify
Bonify is a Canadian-owned Licensed Producer and leading provider of medical cannabis. By maximizing
research findings and strictly adhering to best-in-class practices, quality standards and procedures, Bonify
produces medical cannabis products to help individuals get the most out of life each and every day. With
over 1,000,000 square feet of potential productive capacity at its present site in Winnipeg, Manitoba, Canada,
when at full scale, Bonify will be capable of growing over 100,000 kgs of cannabis annually.
About Algae Dynamics Corp
ADC is engaged in the development of unique health products and pharmaceuticals that utilize hemp,
cannabis and algae oils. We have engaged two Canadian universities to provide research into the use of
extracts from cannabis oil, which we plan to use to develop products that combine the significant health
benefits of Omega-3s derived from algae oil and extracts from cannabis oil. Our research is focused on the
use of cannabis oil in the context of cancer, and the use of cannabis derivatives for the development of novel
pharmacotherapies for mental health.
For more information, visit http://www.algaedynamics.com
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" as that term is defined in Section 27A of the
Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press
release which are not purely historical are forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include,
among other things, use of proceeds and the development, costs and results of current or future actions and
opportunitiesin the sector. Actual results could differfrom those projected in any forward-looking statements
due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new
projects and development stage companies, our ability to raise the additional funding we will need to
continue to pursue our exploration and development program, and our ability to retain important members
of our management team and attract other qualified personnel. These forward-looking statements are made
as of the date of this news release, and we assume no obligation to update the forward-looking statements, or
to update the reasons why actual results could differ from those projected in the forward-looking statements.
Although we believe that any beliefs, plans, expectations and intentions contained in this press release are
reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove
to be accurate.
Investors should consult all the information set forth herein and should also refer to the risk factors disclosure
outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form
10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
INVESTOR RELATIONS CONTACT:
Jack Eversull, President
The Eversull Group, Inc.
jack@theeversullgroup.com
972-571-1624
COMPANY
CONTACT:
Paul Ramsay, President
Algae Dynamics Corp
ramsay@algaedynamics.com
416-704-3040

RADINZ_LAYOUT




 

Author: Cenedella.de

Over the last 4 decades I have been involved in the fight for patient rights in America, and now here in Germany. During my career I have served as a Board of Director for the World Trade Center San Diego and as a Lead Consultant for Deutsche Telekom's Executive Board, Co-Founded the San Diego Software Council and the Dayton Human Trafficking Accords and was Director of LawInfo's Lead Council Program. Previously I was a C-Level Business Development Executive in the technology sector, but also involved with the cannabis industry since 1977. More recently I have been fulltime in the legal medical marijuana industry here in Europe, helping international companies navigate the biggest potential market in the world. This website is light on details due to confidentiality issues with clients but be rest assured I am knowledgeable, professional and with street cred in the industry that can immediately assist your growth in some way. Consulting Services: Sales and Business Development Assist with Strategic Direction Professionally represent your firm Special Projects management Licensing and compliance Sales and Distribution networks Qualify potential partners I am your resource on the ground in Europe, contact me directly to schedule an initial discussion on the German Cannabis-as-Medicine market. Thank you, Philip J. Cenedella IV Call +1.888.206.3264 USA +49.0.151.720.17652 GERMANY Skype: philip.j.cenedella eMail: phil@cenedella.de LinkedIN: https://www.linkedin.com/in/cenedellade/

Comments are closed.